News

Media

Conferences

Conference Coverage

Conference Listing

Publication

Resources

Drug Watch

Latest News

TSND-201 Receives Breakthrough Therapy Designation From FDA for PTSD

By Heidi Anne Duerr, MPH

July 10th 2025

Transcend Therapeutic announces breakthrough therapy designation for TSND-201 for treating PTSD.

sNDA Submitted: Lumateperone for the Prevention of Relapse in Schizophrenia

By Leah Kuntz

July 8th 2025

Johnson & Johnson has submitted an sNDA for Caplyta, showcasing significant relapse prevention in schizophrenia.

The Psychiatric Pipeline in Review: Quarter 2, 2025

By Leah Kuntz

July 7th 2025

What disease states are most prominently featured in recent research? Learn more in this exclusive article.

Positive Results From the Phase 2b Study of BPL-003 in Patients With Treatment-Resistant Depression

By Leah Kuntz

July 1st 2025

New clinical trial results reveal BPL-003's rapid and durable antidepressant effects, paving the way for innovative treatments in treatment-resistant depression.

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

By Leah Kuntz

July 1st 2025

The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals.

...

3 4 5 6 7

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777